The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
Open accessAbstract
OBJECTIVE: To determine whether rheumatoid factor (RF), anti-cyclic citrullinated peptide (CCP) antibodies, or carriage of shared epitope (SE) and PTPN22 genetic susceptibility variants predict response to therapy in patients with rheumatoid arthritis (RA) treated with anti-tumour necrosis factor (TNF) agents. METHODS: UK-wide multicentre collaborations were established to recruit a large cohort of patients treated with anti-TNF drugs for RA. Serum RF, anti-CCP antibody and SE status were determined using commercially available kits. PTPN22 R620W genotyping was performed by Sequenom MassArray. Linear regression analyses were performed to investigate the role of these four factors in predicting response to treatment by 6 months, defined as the absolute change in 28-joint Disease Activity Score (DAS28). RESULTS: Of the 642 patients analysed, 46% received infliximab, 43% etanercept and 11% adalimumab. In all, 89% and 82% of patients were RF and anti-CCP positive, respectively. Patients that were RF negative had a 0.48 (95% CI 0.08 to 0.87) greater mean improvement in DAS28 compared to patients that were RF positive. A better response was also seen among patients that were anti-CCP negative. No association was demonstrated between drug response and SE or PTPN22 620W carriage. CONCLUSION: The presence of RF or anti-CCP antibodies was associated with a reduced response to anti-TNF drugs. However, these antibodies only account for a small proportion of the variance in treatment response. It is likely that genetic factors will contribute to treatment response, but these do not include the well established RA susceptibility loci, SE and PTPN22.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TRAF1–C5 as a Risk Locus for Rheumatoid Arthritis — A Genomewide Study
Plenge, R. M., Seielstad, M., Padyukov, L., Lee, A. T., Remmers, E. F., Ding, B., Liew, A., Khalili, H., Chandrasekaran, A., Davies, L. R. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073491 · Cited by 823
Cited by
Rheumatoid Factors: Clinical Applications
Ingegnoli, F., Castelli, R., & Gualtierotti, R. (2013) · Disease Markers · doi:10.1155/2013/726598 · Cited by 351
Smoking and Rheumatoid Arthritis
Chang, K., Yang, S., Kim, S., Han, K., Park, S., & Shin, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151222279 · Cited by 337
Anti–citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis
Aggarwal, R., Liao, K., Nair, R., Ringold, S., & Costenbander, K. H. (2009) · Arthritis Care & Research · doi:10.1002/art.24827 · Cited by 253
Saevarsdottir, S., Wedrén, S., Seddighzadeh, M., Bengtsson, C., Wesley, A., Lindblad, S., Askling, J., Alfredsson, L., & Klareskog, L. (2011) · Arthritis & Rheumatism · doi:10.1002/art.27758 · Cited by 253
PTPN22: the archetypal non-HLA autoimmunity gene
Stanford, S. M., & Bottini, N. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.109 · Cited by 227
Metadata
- Authors
- Potter, C., Hyrich, K. L., Tracey, A., Lunt, M., Plant, D., Symmons, D. P. M., Thomson, W., Worthington, J., Emery, P., Morgan, A. W., Wilson, A. G., Isaacs, J., & Barton, A.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 68
- Issue
- 1
- Pages
- 69-74
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2098896429
- Cited by
- 240
- References
- 1
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. https://app.cochat.ai/papers/10.1136/ard.2007.084715
- The paper
- Potter, C., Hyrich, K. L., Tracey, A., Lunt, M., Plant, D., Symmons, D. P. M., Thomson, W., Worthington, J., Emery, P., Morgan, A. W., Wilson, A. G., Isaacs, J., & Barton, A. (2009). Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard.2007.084715
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.